Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 152Melanoma 133Lymphoma 124Prostatic Neoplasms 123Carcinoma, Non-Small-Cell Lung 113Multiple Myeloma 106Carcinoma, Renal Cell 92Ovarian Neoplasms 88Leukemia, Myeloid, Acute 83Sarcoma 82Lung Neoplasms 80Leukemia, Lymphocytic, Chronic, B-Cell 80Leukemia 79Colorectal Neoplasms 79Colonic Neoplasms 74Rectal Neoplasms 71Lymphoma, Non-Hodgkin 69Pancreatic Neoplasms 68Carcinoma, Ovarian Epithelial 66Neoplasms 65Lymphoma, Large B-Cell, Diffuse 65Brain Neoplasms 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma, Follicular 58Kidney Neoplasms 58Glioblastoma 57Fallopian Tube Neoplasms 54Carcinoma, Hepatocellular 51Lymphoma, Mantle-Cell 50Central Nervous System Neoplasms 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Hyperthyroidism × Clear all
NCT00080574 2008-03-04

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled
Head & Neck

Hyperthyroidism, Hypothyroidism, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡